Renata Mikolajczak Selected Research

EDDA (NiEDDA)

1/2020	Superior Diagnostic Performance of the GLP-1 Receptor Agonist [Lys40(AhxHYNIC-[99mTc]/EDDA)NH2]-Exendin-4 over Conventional Imaging Modalities for Localization of Insulinoma.
9/2005	Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
1/2005	(99m)Tc-EDDA/HYNIC-octreotate - a new radiotracer for detection and staging of NET: a case of metastatic duodenal carcinoid.
10/2004	Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-octreotide, a somatostatin analog for tumor diagnosis.
4/2004	Clinical usefulness of 99mTc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostics: a pilot study.
4/2004	99mTc-EDDA/HYNIC-TOC in the management of medullary thyroid carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Renata Mikolajczak Research Topics

Disease

6	Neoplasms (Cancer) 12/2020 - 04/2004
4	Thyroid Neoplasms (Thyroid Cancer) 01/2019 - 04/2004
2	Atherosclerotic Plaque (Atheroma) 04/2012 - 09/2009
2	Chronic Kidney Failure (Chronic Renal Failure) 04/2012 - 09/2009
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2011 - 04/2004
2	Carcinoid Tumor (Carcinoid) 01/2005 - 04/2004
2	Neoplasm Metastasis (Metastasis) 04/2004 - 04/2004
1	Insulinoma 01/2020
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2013
1	Myocardial Infarction 01/2011
1	Atherosclerosis 09/2009
1	Inflammation (Inflammations) 09/2009
1	Leiomyosarcoma 04/2004
1	Pheochromocytoma 04/2004
1	Prostatic Neoplasms (Prostate Cancer) 04/2004
1	Melanoma (Melanoma, Malignant) 04/2004

Drug/Important Bio-Agent (IBA)

6	EDDA (NiEDDA)IBA 01/2020 - 04/2004
5	Somatostatin Receptors (Somatostatin Receptor)IBA 12/2020 - 09/2005
4	RadiopharmaceuticalsIBA 08/2016 - 04/2004
4	Octreotide (Sandostatin)FDA LinkGeneric 07/2008 - 04/2004
3	Peptides (Polypeptides)IBA 01/2019 - 09/2005
2	Interleukin-2 (IL2)IBA 04/2012 - 09/2009
2	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 01/2011 - 09/2005
2	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 09/2005 - 10/2004
1	Glucagon-Like Peptide ReceptorsIBA 01/2020
1	Glucagon-Like Peptide-1 ReceptorIBA 01/2020
1	Exenatide (Byetta)FDA Link 01/2020
1	Pharmaceutical PreparationsIBA 01/2019
1	Cholecystokinin B ReceptorIBA 12/2018
1	Cholecystokinin (Pancreozymin)IBA 08/2016
1	GastrinsIBA 08/2016
1	IsotopesIBA 01/2013
1	Biomarkers (Surrogate Marker)IBA 09/2009
1	6-hydrazinopyridine-3-carboxylic acidIBA 07/2008
1	3-Tyr-octreotideIBA 07/2008
1	Radioisotopes (Radionuclides)IBA 09/2005
1	AcidsIBA 09/2005
1	Pentetic Acid (DTPA)FDA LinkGeneric 09/2005
1	LigandsIBA 04/2004
1	Adrenocorticotropic Hormone (ACTH)FDA Link 04/2004

Therapy/Procedure

4	Therapeutics 12/2018 - 09/2005
1	Precision Medicine 01/2019
1	Peritoneal Dialysis 09/2009